Curaleaf Wants to Buy Aurora Cannabis for $272 Million. Is Canopy Growth the Next Marijuana Takeover Target?

Curaleaf launched an unsolicited $272 million bid to acquire Aurora Cannabis (ACB) at $4 per share, marking a fresh wave of consolidation in the cannabis sector. The move puts spotlight on whether Canopy Growth (CGC) could emerge as the next takeover candidate.

ACB shareholders would receive $4.00 cash per share under Curaleaf's proposal, representing a premium to recent trading levels. The bid reflects acquirers hunting for scale and brand portfolios as the industry consolidates through a prolonged downturn.

CGC holds global medical cannabis licenses and established consumer brands, assets that could attract strategic buyers. However, the company's complex corporate structure and ongoing operational turnaround present obstacles for potential acquirers evaluating a deal. Unlike ACB's relatively straightforward profile at a sub-$300 million valuation, CGC's size and restructuring trajectory complicate acquisition math.

The Curaleaf-ACB proposal signals that mid-cap cannabis names with revenue bases and brand equity are back in play as acquisition targets, particularly as operators seek consolidation benefits amid margin pressure.